Friday, 24 Jan 2020

You are here

Reduced Uric Acid from Weight Loss Tied to Triglycerides

Weight loss is one of several nonpharmaceutical interventions to reduce serum urate (SUA) levels and control gout. French researchers examined the role of xanthine oxidase (XO), low-grade inflammation, and weight loss on SUA levels in obese patients.

They examined 154 consecutive patients with severe obesity involved in a bariatric surgery program. Their mean body mass index [BMI] was 47.8 kg/m2 and had a mean 6 month weight loss of 31.3 kg. Weight loss was associated with a modest reduction in SUA levels (-10%) or roughtly a mean loss of 5.5 kg over 6 months. 

The decrease in SUA levels was greatest (-18%) for hyperuricemic patients (n=48). Decreased SUA levels associated with decreased triglycerides levels (p=0.0001) and BMI (p=0.02) but not XO activity, adipokine levels (leptin or adiponectin), insulin resistance, or levels of inflammatory markers.

Weight loss in obese patients was associated with a decrease in both SUA levels and XO activity. However, reductions in SUA levels are partly due to reduction in triglycerides levels. This association strengthens the link between hyperuricemia, gout and the metabolic syndrome.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

Predicting Inpatient Gout Flares

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare:

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.